Literature DB >> 9557754

Processing of the Borna disease virus glycoprotein gp94 by the subtilisin-like endoprotease furin.

J A Richt1, T Fürbringer, A Koch, I Pfeuffer, C Herden, I Bause-Niedrig, W Garten.   

Abstract

Open reading frame IV (ORF-IV) of Borna disease virus (BDV) encodes a protein with a calculated molecular mass of ca. 57 kDa (p57), which increases after N glycosylation to 94 kDa (gp94). The unglycosylated and glycosylated proteins are proteolytically cleaved by the subtilisin-like protease furin. Furin most likely recognizes one of three potential cleavage sites, namely, an arginine at position 249 of the ORF-IV gene product. The furin inhibitor decRVKRcmk decreases the production of infectious BDV significantly, indicating that proteolytic cleavage of the gp94 precursor molecule is necessary for the full biological activity of the BDV glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557754      PMCID: PMC109700          DOI: 10.1128/JVI.72.5.4528-4533.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Detection of a novel Borna disease virus-encoded 10 kDa protein in infected cells and tissues.

Authors:  T Wehner; A Ruppert; C Herden; K Frese; H Becht; J A Richt
Journal:  J Gen Virol       Date:  1997-10       Impact factor: 3.891

Review 2.  The remarkable coding strategy of borna disease virus: a new member of the nonsegmented negative strand RNA viruses.

Authors:  A Schneemann; P A Schneider; R A Lamb; W I Lipkin
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

Review 3.  Immunopathogenesis of Borna disease.

Authors:  L Stitz; B Dietzschold; K M Carbone
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

Review 4.  Molecular biology of borna disease virus: prototype of a new group of animal viruses.

Authors:  J C de la Torre
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Biology and neurobiology of Borna disease viruses (BDV), defined by antibodies, neutralizability and their pathogenic potential.

Authors:  H Ludwig; K Furuya; L Bode; N Klein; R Dürrwald; D S Lee
Journal:  Arch Virol Suppl       Date:  1993

6.  Carbohydrate masking of an antigenic epitope of influenza virus haemagglutinin independent of oligosaccharide size.

Authors:  K Munk; E Pritzer; E Kretzschmar; B Gutte; W Garten; H D Klenk
Journal:  Glycobiology       Date:  1992-06       Impact factor: 4.313

7.  Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.

Authors:  S Hallenberger; V Bosch; H Angliker; E Shaw; H D Klenk; W Garten
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

8.  Sequence and genome organization of Borna disease virus.

Authors:  B Cubitt; C Oldstone; J C de la Torre
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease.

Authors:  A Stieneke-Gröber; M Vey; H Angliker; E Shaw; G Thomas; C Roberts; H D Klenk; W Garten
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

10.  Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation.

Authors:  M Vey; W Schäfer; S Berghöfer; H D Klenk; W Garten
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  25 in total

1.  Furin is involved in baculovirus envelope fusion protein activation.

Authors:  Marcel Westenberg; Hualin Wang; Wilfred F J IJkel; Rob W Goldbach; Just M Vlak; Douwe Zuidema
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Optimal Expression of the Envelope Glycoprotein of Orthobornaviruses Determines the Production of Mature Virus Particles.

Authors:  Madoka Sakai; Yoko Fujita; Ryo Komorizono; Takehiro Kanda; Yumiko Komatsu; Takeshi Noda; Keizo Tomonaga; Akiko Makino
Journal:  J Virol       Date:  2020-12-02       Impact factor: 5.103

3.  N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry.

Authors:  M Perez; M Watanabe; M A Whitt; J C de la Torre
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Genome trimming: a unique strategy for replication control employed by Borna disease virus.

Authors:  Urs Schneider; Martin Schwemmle; Peter Staeheli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  Open reading frame III of borna disease virus encodes a nonglycosylated matrix protein.

Authors:  I Kraus; M Eickmann; S Kiermayer; H Scheffczik; M Fluess; J A Richt; W Garten
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Abundant defective viral particles budding from microglia in the course of retroviral spongiform encephalopathy.

Authors:  R Hansen; S Czub; E Werder; J Herold; G Gosztonyi; H Gelderblom; S Schimmer; S Mazgareanu; V ter Meulen; M Czub
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Enhanced neurovirulence of borna disease virus variants associated with nucleotide changes in the glycoprotein and L polymerase genes.

Authors:  Yoshii Nishino; Darwyn Kobasa; Steven A Rubin; Mikhail V Pletnikov; Kathryn M Carbone
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Molecular chaperone BiP interacts with Borna disease virus glycoprotein at the cell surface.

Authors:  Tomoyuki Honda; Masayuki Horie; Takuji Daito; Kazuyoshi Ikuta; Keizo Tomonaga
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  Persistence of Borna disease virus in naturally infected sheep.

Authors:  Thomas W Vahlenkamp; Andrea Konrath; Matthias Weber; Hermann Müller
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Proteomics computational analyses suggest that the bornavirus glycoprotein is a class III viral fusion protein (gamma penetrene).

Authors:  Courtney E Garry; Robert F Garry
Journal:  Virol J       Date:  2009-09-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.